Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine.
Adolescent
Adult
Aged
Antibodies, Neutralizing
/ immunology
Autoantibodies
/ immunology
Autoimmune Diseases
/ genetics
COVID-19
/ genetics
Female
Genetic Diseases, Inborn
/ genetics
HEK293 Cells
Humans
Interferon-alpha
/ genetics
Male
Middle Aged
Receptor, Interferon alpha-beta
/ deficiency
SARS-CoV-2
/ genetics
Vaccines, Attenuated
/ genetics
Yellow Fever Vaccine
/ adverse effects
Yellow fever virus
/ genetics
Journal
The Journal of experimental medicine
ISSN: 1540-9538
Titre abrégé: J Exp Med
Pays: United States
ID NLM: 2985109R
Informations de publication
Date de publication:
05 04 2021
05 04 2021
Historique:
received:
20
11
2020
revised:
21
12
2020
accepted:
19
01
2021
entrez:
5
2
2021
pubmed:
6
2
2021
medline:
16
2
2021
Statut:
ppublish
Résumé
Yellow fever virus (YFV) live attenuated vaccine can, in rare cases, cause life-threatening disease, typically in patients with no previous history of severe viral illness. Autosomal recessive (AR) complete IFNAR1 deficiency was reported in one 12-yr-old patient. Here, we studied seven other previously healthy patients aged 13 to 80 yr with unexplained life-threatening YFV vaccine-associated disease. One 13-yr-old patient had AR complete IFNAR2 deficiency. Three other patients vaccinated at the ages of 47, 57, and 64 yr had high titers of circulating auto-Abs against at least 14 of the 17 individual type I IFNs. These antibodies were recently shown to underlie at least 10% of cases of life-threatening COVID-19 pneumonia. The auto-Abs were neutralizing in vitro, blocking the protective effect of IFN-α2 against YFV vaccine strains. AR IFNAR1 or IFNAR2 deficiency and neutralizing auto-Abs against type I IFNs thus accounted for more than half the cases of life-threatening YFV vaccine-associated disease studied here. Previously healthy subjects could be tested for both predispositions before anti-YFV vaccination.
Identifiants
pubmed: 33544838
pii: 211761
doi: 10.1084/jem.20202486
pmc: PMC7871457
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Autoantibodies
0
IFNA2 protein, human
0
IFNAR1 protein, human
0
IFNAR2 protein, human
0
Interferon-alpha
0
Vaccines, Attenuated
0
Yellow Fever Vaccine
0
Receptor, Interferon alpha-beta
156986-95-7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIAID NIH HHS
ID : R38 AI140299
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI090023
Pays : United States
Organisme : NHGRI NIH HHS
ID : UM1 HG006504
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI057266
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI088364
Pays : United States
Organisme : NHGRI NIH HHS
ID : U24 HG008956
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001866
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI124690
Pays : United States
Informations de copyright
© 2021 Bastard et al.
Déclaration de conflit d'intérêts
Disclosures: A. Homma reported, "Our institution is a non-profit producer of the yellow fever vaccine. We are public institution, part of our Ministry of Health, and provide vaccine only for National Immunization Program and UNICEF, PAHO Revolving Fund, GAVI, and WHO. We are very much interested to know all relevant scientific issues involved with our vaccine." J.L. Casanova reported a patent to application number 63/055,155, filed July 22, 2020 pending. No other disclosures were reported.
Références
Immunity. 2006 Nov;25(5):695-7
pubmed: 17098200
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Vaccine. 2014 Oct 7;32(44):5769-75
pubmed: 25192973
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Science. 2020 Oct 23;370(6515):
pubmed: 32972995
J Clin Invest. 2021 Jan 4;131(1):
pubmed: 32960813
Arthritis Rheumatol. 2019 May;71(5):756-765
pubmed: 30507062
J Travel Med. 2016 Jul 04;23(5):
pubmed: 27378369
Med (N Y). 2020 Dec 18;1(1):14-20
pubmed: 33363283
J Exp Med. 2019 Sep 2;216(9):2057-2070
pubmed: 31270247
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Lancet. 2001 Jul 14;358(9276):91-7
pubmed: 11463409
Nature. 2021 Feb;590(7845):320-325
pubmed: 33260195
Expert Rev Vaccines. 2016 Jun;15(6):681-91
pubmed: 27087465
J Clin Immunol. 2020 Jan;40(1):24-64
pubmed: 31953710
J Exp Med. 2015 Sep 21;212(10):1641-62
pubmed: 26304966
J Infect Dis. 2008 Aug 15;198(4):500-7
pubmed: 18598196
Sci Immunol. 2020 Jul 10;5(49):
pubmed: 32651211
Nat Methods. 2016 Feb;13(2):109-10
pubmed: 26820543
Arthritis Rheumatol. 2016 Jul;68(7):1677-87
pubmed: 26815287
Lancet. 2001 Jul 14;358(9276):121-2
pubmed: 11463415
J Clin Invest. 2015 Nov 2;125(11):4135-48
pubmed: 26457731
Hum Genet. 2020 Jun;139(6-7):783-794
pubmed: 32419033
J Immunol. 1982 Jul;129(1):1-3
pubmed: 6177744
Dtsch Med Wochenschr. 2017 Aug;142(16):1219-1222
pubmed: 28810279
Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):3053-8
pubmed: 23391734
Vaccine. 2014 Nov 20;32(49):6676-82
pubmed: 24837504
J Cell Biol. 2015 May 25;209(4):579-93
pubmed: 26008745
Science. 2020 Oct 23;370(6515):
pubmed: 32972996
Hum Vaccin. 2005 Sep-Oct;1(5):207-14
pubmed: 17012867
PLoS Pathog. 2011 Jan 13;7(1):e1001255
pubmed: 21249176
Cells. 2019 Dec 27;9(1):
pubmed: 31892200
Immunity. 2019 Apr 16;50(4):907-923
pubmed: 30995506
J Clin Immunol. 2020 Jan;40(1):66-81
pubmed: 32048120
Clin Infect Dis. 2020 Nov 30;:
pubmed: 33252644
J Travel Med. 2020 Nov 9;27(7):
pubmed: 32965473
Genome Res. 2001 May;11(5):863-74
pubmed: 11337480
Nat Genet. 2014 Mar;46(3):310-5
pubmed: 24487276
J Allergy Clin Immunol. 2019 Jul;144(1):309-312.e10
pubmed: 30826365
Vaccine. 2012 Jul 13;30(33):5038-58
pubmed: 22561144
Nat Methods. 2010 Apr;7(4):248-9
pubmed: 20354512
J Biol Chem. 2000 Aug 4;275(31):23981-5
pubmed: 10825167
Nat Genet. 2003 Mar;33(3):388-91
pubmed: 12590259
Sci Transl Med. 2015 Sep 30;7(307):307ra154
pubmed: 26424569
Expert Rev Vaccines. 2005 Aug;4(4):553-74
pubmed: 16117712
J Exp Med. 2018 Oct 1;215(10):2567-2585
pubmed: 30143481
Nat Commun. 2016 Dec 23;7:13992
pubmed: 28008925
Lancet. 2001 Jul 14;358(9276):98-104
pubmed: 11463410
PLoS Med. 2006 Jul;3(7):e289
pubmed: 16784312